TransCode Therapeutics In...

NASDAQ: RNAZ · Real-Time Price · USD
10.75
-0.30 (-2.71%)
At close: Aug 15, 2025, 1:09 PM

TransCode Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
n/a n/a n/a n/a
Cost of Revenue
n/a n/a 98.61K 42.47K
Gross Profit
n/a n/a -98.61K -42.47K
Operating Income
-15.66M -19.42M -18.67M -6.15M
Interest Income
684.00 5.29K 20.41K 664.00
Pretax Income
-16.79M -18.55M -17.56M -6.84M
Net Income
-16.75M -18.55M -35.13M -6.94M
Selling & General & Admin
5.95M 7.15M 8.43M 3.4M
Research & Development
9.62M 12.26M 10.23M 2.75M
Other Expenses
n/a 0.00 -1.08M -278.33K
Operating Expenses
15.66M 19.42M 17.59M 5.87M
Interest Expense
26.81K 55.9K 17.56M 95.07K
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
-15.66M 19.42M 17.59M 5.87M
Income Tax Expense
n/a n/a 17.56M 95.07K
Shares Outstanding (Basic)
356.12K 5.42K 16.22K 10.53K
Shares Outstanding (Diluted)
356.12K 5.42K 16.22K 10.53K
EPS (Basic)
-47.14 -3.45K -73.19K -648
EPS (Diluted)
-47.14 -3.45K -1.08K -648
EBITDA
-16.19M -17.97M -17.47M -6.11M
EBIT
-14.57M -18.49M -17.56M -6.15M
Depreciation & Amortization
534.86K 516.75K 98.61K 42.47K